Abstract:Efforts to develop biomarker-targeted anti-cancer therapies have progressed rapidly in recent years. Six antibodies acting on programmed death ligand 1 or programmed death 1 pathways were approved in 75 cancer indications between 2015 and 2021. With efforts to expedite regulatory reviews of promising therapies, several targeted cancer therapies have been granted accelerated approval on the basis of single-arm phase II trials. And yet, in the absence of randomization, patient outcomes may not have been studied under standard of care chemotherapies for emerging biomarker subpopulations prior to the submission of an accelerated approval application. Historical control rates used in single arm studies often arise as population averages, lacking specificity to the targeted subgroup. For example, a recent phase III trial of atezolizumab in patients with metastatic urothelial carcinoma found a 21.6% response rate to standard of care chemotherapy in the biomarker subgbroup of interest, much higher than the historical control rate of 10% that had been used to declare success in the preceding phase II trial. Innovations in design methodology are needed to enable efficient implementation of randomized trials for agents that target biomarker subpopulations. This article proposes three randomized designs for early phase biomarker-guided oncology clinical trials. Each design utilizes the optimal efficiency predictive probability method to monitor multiple biomarker subpopulations for futility. A simulation study motivated by the results reported in the atezolizumab trial is used to evaluate the operating characteristics of the various designs. Our findings suggest that efficient statistical design can be conducted with randomization and futility stopping to effectively acquire more evidence pertaining to comparative efficacy before deciding to conduct a phase III confirmatory trial.

Combining biomarkers by maximizing the true positive rate for a fixed false positive rate

Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkers

Developing Biomarker Combinations in Multicenter Studies via Direct Maximization and Penalization

Measures of Performance and Clinical Superiority Thresholds for 'Test-and-treat' Predictive Biomarkers

False Discovery Rate Control in Cancer Biomarker Selection Using Knockoffs.

Combining Biomarkers to Improve Diagnostic Accuracy in Detecting Diseases With Group‐Tested Data

Boosting the concordance index for survival data - a unified framework to derive and evaluate biomarker combinations

Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers

Hybrid Design Evaluating New Biomarkers when There is an Existing Screening Test

Optimal Marker-Strategy Clinical Trial Design to Detect Predictive Markers for Targeted Therapy

On the Optimal Combination of Elliptically Distributed Biomarkers to Improve Diagnostic Accuracy

Computation and Selection of Optimal Biomarker Combinations by Integrative ROC Analysis Using CombiROC

A cost-sensitive Bayesian combiner for reducing false positives in mammographic mass detection

Test for Incremental Value of New Biomarkers Based on OR Rules

A distribution-free smoothed combination method of biomarkers to improve diagnostic accuracy in multi-category classification

Sample size and performance estimation for biomarker combinations based on pilot studies with small sample sizes

Optimal predictive probability designs for randomized biomarker-guided oncology trials

A novel method to guide biomarker combinations to optimize the sensitivity

Medical diagnostic accuracy measures: an innovative approach based on the area under predictive values curves

Selection and combination of biomarkers using ROC method for disease classification and prediction

Assessing clinical response in early oncology development with a predictive biomarker